Verve Therapeutics, Inc.

As of March 31, 2025, Verve Therapeutics, Inc. has 89.14M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 6.60, and the price-to-book ratio stands at -0.51.

These figures are as of March 31, 2025. The EV/Sales ratio of 1.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of March 31, 2025, Verve Therapeutics, Inc. maintains a current ratio of 9.84, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -26.89, reflecting losses generated across the asset base.

Over the twelve months ended March 31, 2025, Verve Therapeutics, Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -349.68 and net profit margin of -303.64 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -35.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.72, meaning Verve Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2025, Verve Therapeutics, Inc. has an Altman Z-Score of -0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.